A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) INCT036413131.

被引：0
|
作者：
Das, Satya
Whisenant, Jennifer
Doyle, Austin
Allegra, Carmen Joseph
Berlin, Jordan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] NCI, Rockville, MD USA
[3] NSABP Fdn, Gainesville, FL USA
[4] Univ Florida, Gainesville, FL USA
[5] Vanderbilt Univ, Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.TPS175
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS175
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Berzosertib plus irinotecan in patients with TP53 mutant gastric/gastroesophageal junction adenocarcinoma: A phase II study
    Das, Satya
    Ayers, G. Dan
    Whisenant, Jennifer
    Saeed, Anwaar
    Kim, Edward
    Florou, Vaia
    Yacoub, George
    Ivy, Percy
    Kunos, Charles
    Berlin, Jordan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [2] A phase II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ) adenocarcinoma
    Iqbal, Syma
    El-Khoueiry, Anthony B.
    Yang, Dongyun
    Paez, David
    Duddalwar, Vinay
    Zhang, Wu
    Agafitei, Raluca Dana
    Lujan, Ramona
    Cole, Sarah
    Ning, Yan
    El-Khoueiry, Rita
    Loupakis, Fotios
    Wakatsuki, Takeru
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Shah, MA
    Ilson, D
    Ramanathan, RK
    Levner, A
    D'Adamo, D
    Schwartz, L
    Casper, E
    Schwartz, GK
    Kelsen, DP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 314S - 314S
  • [4] Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study
    Di Lauro, L.
    Giacinti, L.
    Arena, M. G.
    Fattoruso, S. I.
    Foggi, P.
    Lopez, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li Ning
    Li Zhi
    Fu Qiang
    Zhang Bin
    Zhang Jian
    Wan XiangBin
    Lu Chaomin
    Wang Jinbang
    Deng Wenying
    Wei Chen
    Ma Yijie
    Bie Liangyu
    Wang Mengyu
    Luo Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, N.
    Li, Z.
    Fu, Q.
    Zhang, B.
    Zhang, J.
    Wan, X.
    Lu, C.
    Wang, J.
    Deng, W.
    Wei, C.
    Ma, Y.
    Bie, L.
    Wang, M.
    Luo, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1302 - S1302
  • [7] A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer
    Stockton, Shannon
    Soares, Heloisa P.
    Dayyani, Farshid
    Saeed, Anwaar
    Kim, Edward S.
    Jin, Ning
    Yacoub, George Hosni
    Whisenant, Jennifer
    Ayers, G. Dan
    Gore, Steven
    Das, Satya
    Berlin, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
    Wood, Anthony C.
    Zhang, Yonghong
    Mo, Qianxing
    Cen, Ling
    Fontaine, Jacques
    Hoffe, Sarah E.
    Frakes, Jessica
    Dineen, Sean P.
    Pimiento, Jose M.
    Walko, Christine M.
    Mehta, Rutika
    ONCOLOGIST, 2022, 27 (04): : 307 - 313
  • [9] A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur Gregory Ang
    Mulder, Karen E.
    Brezden-Masley, Christine
    Vickers, Michael M.
    Monzon, Jose Gerard
    Kennecke, Hagen F.
    Goel, Rakesh
    Ghosh, Sunita
    Marginean, Horia
    Vos, Larissa Joy
    Raynard, SeeSee Juliana
    Young, Kristine Lee
    Fields, Anthony L. A.
    Maroun, Jean Alfred
    Spratlin, Jennifer L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345